Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review

Banerji, Aleena; Lax, Timothy; Guyer, Autumn; Hurwitz, Shelley; Camargo, Carlos A.; Long, Aidan A.

doi:10.1016/j.jaip.2014.04.010

Cited by 77 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since their commercialization, the US Food and Drug Administration reported more than 300 fatalities [10][11][12].…”

Section: Taxanesmentioning

confidence: 99%

“…Yet this method is time-consuming and necessitates a 1:1 nursing ratio [10]. Symptoms are limited to the skin (e.g., flushing) or involve a single organ/system and are mild (e.g., mild back pain) 2 Moderate Symptoms involve at least 2 organs/systems (e.g., flushing and dyspnea), but there is no significant decrease in blood pressure or oxygen saturation 3 Severe Symptoms typically involve at least 2 organs/systems, and there is a significant decrease in blood pressure (systolic ≤90 mmHg and/or syncope) and/or oxygen saturation (≤92 %) …”

Section: Rapid Drug Desensitization To Taxanesmentioning

confidence: 99%

See 1 more Smart Citation

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients' survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, and more, and examples of immunemediated and inflammatory diseases that respond to monoclonal antibodies include rheumatoid arthritis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, psoriasis and psoriatic arthritis, Wegener's granulomatosis, microscopic polyangiitis, ankylosing spondylitis, plaque psoriasis, and asthma. Neoplastic diseases include non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and colorectal, breast, gastric, and lung cancer. The clinical presentation of drug hypersensitivity reactions ranges from mild cutaneous reactions to lifethreatening symptoms including anaphylaxis. Rapid drug desensitization (RDD) has become a groundbreaking approach to the management of immediate drug hypersensitivity reactions IgE and non-IgE mediated. It is the only effective procedure that enables sensitized patients to receive the full treatment dose safely, thus representing an important advance in the patients' treatment and prognosis. The aim of this review is to provide an update on hypersensitivity reactions to commonly used monoclonal and taxanes, their clinical presentations, diagnosis, and the use of RDD for their management.

show abstract

“…Since their commercialization, the US Food and Drug Administration reported more than 300 fatalities [10][11][12].…”

Section: Taxanesmentioning

confidence: 99%

Section: Rapid Drug Desensitization To Taxanesmentioning

confidence: 99%

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…Drug desensitization protocols and reviews of approaches were presented in a number of studies. [84][85][86][87] Of clinical note, a case series suggested that intravenous use of methylprednisolone sodium succinate resulted in allergic reactions in children with milk allergy that was traced to likely milk protein contamination of lactose in this preparation, 88 and a case report added to the limited literature with the suggestion that antihistamines can induce urticaria. 89 Several insights of importance for diagnosis and potential future management of drug allergy were reported.…”

Section: Drug Allergymentioning

confidence: 99%

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014

Sicherer

Leung

2015

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2014. Studies on food allergy suggest worrisomely high rates of peanut allergy and food-induced anaphylaxis-related hospitalizations. Evidence is mounting to support the theory that environmental exposure to peanut, such as in house dust, especially with an impaired skin barrier attributed to atopic dermatitis (AD) and loss of function mutations in the filaggrin gene, is a risk factor for sensitization and allergy. Diagnostic tests are improving, with early studies suggesting the possibility of developing novel cellular tests with increased diagnostic utility. Treatment trials continue to show the promise and limitations of oral immunotherapy, and mechanistic studies are elucidating pathways that might define the degree of efficacy of this treatment. Studies have also provided insights into the prevalence and characteristics of anaphylaxis and insect venom allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity levels are related to the severity of reactions. Advances in drug allergy include identification of HLA associations for penicillin allergy and a microRNA biomarker/mechanism for toxic epidermal necrolysis. Research identifying critical events leading to skin barrier dysfunction and the polarized immune pathways that drive AD have led to new therapeutic approaches in the prevention and management of AD.

show abstract

“…In 1 study, of 36 dogs with cancer receiving Taxol ® , 64% developed substantial hypersensitivity reactions despite premedication with antihistamines and corticosteroids . Because Taxol ® is contraindicated in human patients with a history of past Taxol ® hypersensitivity reactions, by standards used in humans Taxol ® would be contraindicated in most dogs . In addition to these Cremophor ® ‐associated hypersensitivy reactions, paclitaxel's use in dogs was associated with expected toxicities based on its mechanism of action.…”

Section: Paclitaxel's Broad Spectrum Of Activity In Human Cancermentioning

confidence: 99%

A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs

Khanna

Rosenberg

Vail

2015

Veterinary Internal Medicne

107

View full text Add to dashboard Cite

Paclitaxel is a commonly used chemotherapeutic agent with a broad spectrum of activity against cancers in humans. In 1992, paclitaxel was approved by the U.S. Food and Drug Administration (FDA) as Taxol® for use in advanced ovarian cancer. Two years later, it was approved for the treatment of metastatic breast cancer. Paclitaxel was originally isolated from the bark of the Pacific yew tree, Taxus brevifolia in 1971. Taxanes are a family of microtubule inhibitors. As a member of this family, paclitaxel suppresses spindle microtubule dynamics. This activity results in the blockage of the metaphase‐anaphase transitions, and ultimately in the inhibition of mitosis, and induction of apoptosis in a wide spectrum of cancer cells. Additional anticancer activities of paclitaxel have been defined that are independent of these effects on the microtubules and may include the suppression of cell proliferation as well as antiangiogenic effects. Based on its targeting of a fundamental feature of the cancer phenotype, the mitotic complex, it is not surprising that paclitaxel has been found to be active in a wide variety of cancers in humans. This review summarizes the evidence in support of paclitaxel's broad anticancer activity and introduces the rationale for, and the progress in development of novel formulations of paclitaxel that may preferentially target cancers and that are not associated with the risks for hypersensitivity in dogs. Of note, a novel nanoparticle formulation of paclitaxel that substantially limits hypersensitivity was recently given conditional approval by the FDA Center for Veterinary Medicine for use in dogs with resectable and nonresectable squamous cell carcinoma and nonresectable stage III, IV and V mammary carcinoma.

show abstract

Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review

Cited by 77 publications

References 23 publications

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014

A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs

Contact Info

Product

Resources

About